Vertex Pharmaceuticals (VRTX) fundamentals: P/E, valuation, undervalued?
Vertex Pharmaceuticals · Health Care · ref. ETF XLV · price $485.22
In short — Vertex Pharmaceuticals trades at 28.3× earnings (P/E), 24.1× forward, with a net margin of 35.0 % and revenue growth of +13 %. Read: Average P/E (P/E 28 (near the ~20-25 average)).
Is Vertex Pharmaceuticals stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$485.22+17.7% over range
Oct 14, 25low $407.9 · high $557.96Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
80% recommend buying · 10 analysts
Valuation : Average P/E — P/E 28 (near the ~20-25 average)
Valuation
28.3
P/E (price/earnings)
24.1
Forward P/E
3.53
PEG
6.1
Price/book (P/B)
$122.9B
Market cap
17.17
EPS
Profitability & growth
35.0 %
Net margin
+13 %
Revenue growth
+8 %
Earnings growth
$2.0B
Total debt
Vertex Pharmaceuticals income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $8.9B | $3.3B | 37.2 % |
| 2023 | $9.9B | $3.6B | 36.7 % |
| 2024 | $11.0B | $-536M | -4.9 % |
| 2025 | $12.0B | $4.0B | 32.9 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Vertex Pharmaceuticals's P/E and is the stock undervalued? What's a good P/E?
Vertex Pharmaceuticals's P/E is 28.3 (forward 24.1). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Average P/E".
Is Vertex Pharmaceuticals profitable?
Vertex Pharmaceuticals has a net margin of 35.0 % (EPS 17.17). The company is profitable.
Is VRTX stock expensive?
Our read: "Average P/E" — P/E 28 (near the ~20-25 average). Cross-check with growth and sector.
💬 A question about Vertex Pharmaceuticals? The JPI assistant answers using our backtest data.
Keep exploring Vertex Pharmaceuticals